Two Instrument Comparison of Reagents From a US FDA-Approved Assay for the Assessment of Ki-67 in High-Risk Early Breast Cancer

The objective of this study was to measure concordance of results obtained from the US Food and Drug Administration–approved Ki-67 immunohistochemistry MIB-1 pharmDx assay performed on the Dako Omnis automated staining instrument (Omnis) versus results produced from the assay reagents applied using...

Descripción completa

Detalles Bibliográficos
Autores principales: Komforti, Miglena, Downs-Kelly, Erinn, Sapunar, Francisco, Wijayawardana, Sameera R., Gruver, Aaron M., Badve, Sunil S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Technical Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444283/
https://www.ncbi.nlm.nih.gov/pubmed/35880975
http://dx.doi.org/10.1097/PAI.0000000000001050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444283/
https://www.ncbi.nlm.nih.gov/pubmed/35880975
http://dx.doi.org/10.1097/PAI.0000000000001050

Ejemplares similares